Benito Munoz
Keine laufenden Positionen mehr
Profil
Benito Munoz worked as a Director in Research Laboratories at Merck & Co., Inc. from 1999 to 2008.
He then worked as a Director in Medicinal Chemistry at The Broad Institute, Inc. from 2009 to 2013.
After that, he worked as a Director at Karyopharm Therapeutics, Inc. and as an Executive Vice President in Drug Discovery at Proteostasis Therapeutics, Inc. from 2016 to 2017.
Munoz holds a graduate degree from Brock University and a doctorate degree from the University of Toronto.
Ehemalige bekannte Positionen von Benito Munoz
| Unternehmen | Position | Ende |
|---|---|---|
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.11.2013 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01.10.2008 |
| KARYOPHARM THERAPEUTICS INC. | Director/Board Member | - |
| PROTEOSTASIS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Benito Munoz
| Brock University | Graduate Degree |
| University of Toronto | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
